-
Pediatric blood & cancer · Feb 2014
Comparative StudyImatinib cessation in children and adolescents with chronic myeloid leukemia in chronic phase.
- Frédéric Millot, Alexander Claviez, Guy Leverger, Selim Corbaciglu, Andreas H Groll, and Meinolf Suttorp.
- Inserm CIC 0802, University Hospital, Poitiers, France.
- Pediatr Blood Cancer. 2014 Feb 1; 61 (2): 355-7.
AbstractImatinib can be safely discontinued in adults with chronic myeloid leukemia (CML) where there is a prolonged complete molecular response (CMR). No data are available in the pediatric population. Six children with CML discontinued imatinib by themselves. Only three of them were in CMR but for <2 years. A significant increase in transcript level was observed in all six patients after cessation of imatinib and five patients lost the major molecular response (MMR). Four patients regained the MMR within 3 months. Cessation of imatinib in children is not recommended outside a trial, particularly in patients without prolonged CMR.© 2013 Wiley Periodicals, Inc.
Notes
Knowledge, pearl, summary or comment to share?You can also include formatting, links, images and footnotes in your notes
- Simple formatting can be added to notes, such as
*italics*,_underline_or**bold**. - Superscript can be denoted by
<sup>text</sup>and subscript<sub>text</sub>. - Numbered or bulleted lists can be created using either numbered lines
1. 2. 3., hyphens-or asterisks*. - Links can be included with:
[my link to pubmed](http://pubmed.com) - Images can be included with:
 - For footnotes use
[^1](This is a footnote.)inline. - Or use an inline reference
[^1]to refer to a longer footnote elseweher in the document[^1]: This is a long footnote..